AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
As of today, AstraZeneca(AZN) shares are valued at $165.08. The company's market cap stands at 256.02B, with a P/E ratio of 24.48 and a dividend yield of 1.90%.
On 2026-08-20, AstraZeneca(AZN) stock moved within a range of $161.48 to $165.57. With shares now at $165.08, the stock is trading +2.2% above its intraday low and -0.3% below the session's peak.
Trading activity shows a volume of 3.74M, compared to an average daily volume of 3.42M.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.
AZN News
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...
...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...
Analyst ratings
87%
of 30 ratingsMore AZN News
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident...
AstraZeneca (AZN) announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line the...
Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful...
In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca, with a price target of p16,500.00. Unlock power...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.